14th Sep 2007 07:00
Bespak PLC14 September 2007 Bespak - Interim Management Statement Bespak plc, a leader in medical devices for inhaled drug delivery andanaesthesia, issues today its Interim Management Statement for the period, 29April 2007 to 14 September 2007. Trading for period has been in line with the Board's expectations with goodperformances in both our inhaled drug delivery and anaesthesia segments. On 27 June 2007 we announced that Nektar Therapeutics and Pfizer had revised their short term forecasts for their Exubera(R) inhalation device and as a result we were embarking on a consultation process with our employees involved in its production. We remain in detailed discussions with Nektar on potential strategies to address the short- to medium-term supply of the Exubera(R) inhaler. On 17 July 2007, we acquired, for a modest consideration, through a newly formedsubsidiary company (Integrated Aluminium Components Limited), certain assets ofDecorpart Ltd from its administrators. Decorpart produces ferrules used in ourmetered dose inhaler valves and this acquisition secures the supply chain forour business, and supplies third parties. The Company will hold its AGM on September 26th 2007 and publish interim resultsin December 2007. For further information, please contact:Bespak plcMark Throdahl, Chief Executive Tel: +44 (0) 1908 552600Jonathan Glenn, Group Finance Director MaitlandLiz Morley Tel: +44 (0) 207 3795151Brian Hudspith This Interim Management Statement is prepared for and addressed only to theCompany's shareholders as a whole and to no other person. The Company, itsdirectors, employees, agents or advisers do not accept or assume responsibilityto any other person to whom this Interim Management Statement is shown or intowhose hands it may come and any such responsibility or liability is expresslydisclaimed. Statements contained in this Interim Management Statement are basedon the knowledge and information available to the Company's Directors at thedate it was prepared and therefore the facts stated and views expressed maychange after that date. By their nature, the statements concerning the risks anduncertainties facing the Company in this Interim Management Statement involveuncertainty since future events and circumstances can cause results anddevelopments to differ materially from those anticipated. To the extent thatthis Interim Management Statement contains any statement dealing with any timeafter the date of its preparation such statement is merely predictive andspeculative as it relates to events and circumstances which are yet to occur.The Company undertakes no obligation to update these forward-looking statements. About Bespak plc Bespak plc is a leader in medical devices for inhaled drug delivery andanaesthesia. The Group develops drug delivery systems for the pharmaceuticalindustry and disposable airway management products for critical care settings inhospitals. Bespak develops and manufactures metered dose inhaler valves, actuators,compliance aids, dry powder devices, disposable face masks, breathing circuitsand laryngeal tubes. The Group has facilities in King's Lynn and Milton Keynesin the UK, Indianapolis, Indiana and Kent, Ohio in the US, and a liaison officein Mumbai, India. Bespak is a public company quoted on the full list of theLondon Stock Exchange (LSE: BPK). For more information, please visitwww.bespak.com This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
CSRT.L